Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates-Reference-Cited by-同舟云学术

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

Published:2005-08 Issue:8 Volume:16 Page:1311-1319
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Folprecht G.,Grothey A.,Alberts S.,Raab H.-R.,Köhne C.-H.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/16/8/1311/318515/mdi246.pdf

Reference63 articles.

1. Estimates of cancer incidence and mortality in Europe in 1995;Bray;Eur J Cancer,2002

2. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer;Andre;N Engl J Med,2004

3. Resection of colorectal liver metastases;Scheele;World J Surg,1995

4. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases;Fong;Ann Surg,1999

5. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients;Nordlinger;Association Francaise de Chirurgie. Cancer,1996

Cited by 569 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial;Anti-Cancer Drugs;2024-08-07

2. Robotic Stereotactic Body Radiation Therapy for Oligometastatic Liver Metastases: A Systematic Review of the Literature and Evidence Quality Assessment;Diagnostics;2024-05-19

3. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial;PLOS Medicine;2024-05-10

4. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study);Acta Oncologica;2024-05-02

5. Explanatory Role of Conversion Surgery as a Mediator of the Mortality Risk Difference Between Patients With Unresectable Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR Agents Versus Bevacizumab;Clinical Colorectal Cancer;2024-05